U.S. Department of Health and Human Services
Clinical Trials Search Results
Search results 1 - 10 of 45 for FDA-Approved HIV Drugs, Triumeq
Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations
Condition: HIV Infections
NCT ID: NCT02354053- Green tick iconRecruiting
- Email this trial
SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over
Condition: HIV
NCT ID: NCT02509195- Red stop iconCompleted
- Email this trial
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
Condition: HIV Infections
NCT ID: NCT03760458- Green tick iconNot yet recruiting
- Globe iconEn español
- Email this trial
Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs
Condition: Human Immunodeficiency Virus
NCT ID: NCT02659761- Green tick iconRecruiting
- Email this trial
Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients
Condition: HIV
NCT ID: NCT02596334- Red stop iconTerminated
- Email this trial
Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany
Condition: HIV Infections
NCT ID: NCT02342769- Red stop iconCompleted
- Email this trial
Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
Condition: HIV; Acute HIV Infection
NCT ID: NCT02384395- Green tick iconRecruiting
- Email this trial
To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers
Condition: HIV Infections
NCT ID: NCT03441984- Red stop iconCompleted
- Email this trial
Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet
Condition: HIV
NCT ID: NCT02569346- Red stop iconCompleted
- Email this trial
Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD)
Condition: HIV-1 Infection
NCT ID: NCT02067767- Red stop iconCompleted
- Email this trial
Email Updates
